文献速递消化道肿瘤与早癌消化内镜

基于人群结直肠癌筛查中粪便隐血试验间期癌的发生率:系统综述与Meta分析

Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis.
PubMed 文献 · Gut · 2018-06-22

该系统综述与Meta分析比较了粪便免疫化学检测(FIT)与愈创木脂粪便隐血试验(gFOBT)阴性后间期结直肠癌(iCRC)的发生率。共纳入29项研究,含6,987,825例检测阴性者。FIT阴性后iCRC的合并发生率为每10万人年20例(95%CI 14-29),gFOBT阴性后为每10万人年34例(95%CI 20-57);FIT与gFOBT的iCRC合并发生率比为0.58(95%CI 0.32-1.07)。

要点

  • FIT阴性后iCRC合并发生率为20/10万人年(95%CI 14-29),gFOBT阴性后为34/10万人年(95%CI 20-57)。
  • FIT与gFOBT的iCRC合并发生率比为0.58(95%CI 0.32-1.07),敏感性分析为0.36(95%CI 0.17-0.75)。
  • gFOBT阴性后iCRC发生率高于FIT阴性后,支持将FIT作为结直肠癌筛查工具。

核心结论

  • gFOBT阴性后iCRC发生率高于FIT阴性后,支持使用FIT而非gFOBT作为结直肠癌筛查工具。

研究设计与样本

  • 检索Ovid Medline、Embase、Cochrane Library、Science Citation Index、PubMed和Google Scholar自建库至2017年12月12日的文献。
  • 纳入平均风险筛查人群中关于FIT或gFOBT后iCRC的研究,共识别7,426条记录并纳入29项研究。
  • Meta分析纳入6,987,825例检测阴性者数据,记录11,932例筛查检出结直肠癌和5,548例gFOBT或FIT后iCRC。
  • 采用随机效应泊松回归模型计算每10万人年的合并iCRC发生率。

主要发现

  • FIT阴性后iCRC合并发生率为每10万人年20例(95%CI 14-29;I²=99%)。
  • gFOBT阴性后iCRC合并发生率为每10万人年34例(95%CI 20-57;I²=99%)。
  • FIT与gFOBT的iCRC合并发生率比为0.58(95%CI 0.32-1.07;I²=99%),敏感性分析为0.36(95%CI 0.17-0.75;I²=10%)。
  • 每1例FIT后iCRC对应2.6例筛查检出结直肠癌(比值1:2.6);gFOBT后iCRC与筛查检出结直肠癌的比值为1:1.2。
  • 年龄低于60岁和第三轮筛查与较低的iCRC发生率显著相关。

关键数值与推荐

  • 17项提供FIT结果的研究中,使用的粪便血红蛋白阳性截断值中位数为20(范围10-200)µg Hb/g粪便。

临床怎么用

  • 原文结论支持将FIT而非gFOBT用作结直肠癌筛查工具。

局限性

  • FIT与gFOBT的iCRC合并发生率比95%CI为0.32-1.07,未达统计学显著。
  • FIT和gFOBT的iCRC合并发生率分析异质性均为I²=99%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Faecal immunochemical tests (FITs) are replacing guaiac faecal occult blood tests (gFOBTs) for colorectal cancer (CRC) screening. Incidence of interval colorectal cancer (iCRC) following a negative stool test result is not yet known. We aimed to compare incidence of iCRC following a negative FIT or gFOBT. DESIGN: We searched Ovid Medline, Embase, Cochrane Library, Science Citation Index, PubMed and Google Scholar from inception to 12 December 2017 for citations related to CRC screening based on stool tests. We included studies on FIT or gFOBT iCRC in average-risk screening populations. Main outcome was pooled incidence rate of iCRCs per 100 000 person-years (p-y). Pooled incidence rates were obtained by fitting random-effect Poisson regression models. RESULTS: We identified 7 426 records and included 29 studies. Meta-analyses comprised data of 6 987 825 subjects with a negative test result, in whom 11 932 screen-detected CRCs and 5 548 gFOBT or FIT iCRCs were documented. Median faecal haemoglobin (Hb) positivity cut-off used was 20 (range 10-200) µg Hb/g faeces in the 17 studies that provided FIT results. Pooled incidence rates of iCRC following FIT and gFOBT were 20 (95% CI 14 to 29; I2=99%) and 34 (95% CI 20 to 57; I2=99%) per 100 000 p-y, respectively. Pooled incidence rate ratio of FIT versus gFOBT iCRC was 0.58 (95% CI 0.32 to 1.07; I2=99%) and 0.36 (95% CI 0.17 to 0.75; I2=10%) in sensitivity analysis. For every FIT iCRC, 2.6 screen-detected CRCs were found (ratio 1:2.6); for gFOBT, the ratio between iCRC and screen-detected CRC was 1:1.2. Age below 60 years and the third screening round were significantly associated with a lower iCRC rate. CONCLUSION: A negative gFOBT result is associated with a higher iCRC incidence than a negative FIT. This supports the use of FIT over gFOBT as CRC screening tool.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Wieten E, Schreuders EH, Grobbee EJ, et al. Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis. Gut. 2018. PMID: 29934436. doi:10.1136/gutjnl-2017-315340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。